UTSpeaks: A medicated nation Has Australia lost its way in a pharmaceutical love affair? Professor Charlie Benrimoj and Associate Professor Mary Bebawy from the University of Technology, Sydney present at this public lecture on prescription medication held on 13 September, 2011. How many pills will you take today? Do you really need them? What good (and bad) will they do you? For many of us prescription medications mean the difference between good and ill-health. There’s no denying their important place in fostering well-being for many. But is it time to reflect on the complex forces at work when managing disease and medications and how this impacts you the consumer? Featuring leading UTS researchers in pharmacy and using example case studies, this public lecture takes a critical look at how medications are prescribed and consumed in Australia. It considers whether we are getting value for money, the ideal health outcomes we hope for and whether new approaches to the responsible use and explanation of medications could be adopted. Speakers: Professor Shalom (Charlie) Benrimoj Charlie Benrimoj is head of the newly-created UTS School of Pharmacy. Formerly he was Foundation Professor of Pharmacy Practice then Dean of the Faculty of Pharmacy and then Pro-Vice Chancellor (Strategic Planning) at the University of Sydney. He is a visiting professor at the University of Granada with research interests in the future of community pharmacy. He is widely published - co-authoring Community Pharmacy: Strategic Change Management in 2007. He was Australian Pharmacist of the Year in 2000 and received the Andre Bedat award in 2010 from the International Pharmacy Federation. Associate Professor Mary Bebawy Mary Bebawy has spent more than 14 years in research and teaching positions in academia and two years in industry as a post doctoral preclinical drug development scientist with Johnson and Johnson, Research. She has consulted to academia and industry on assay development, drug discovery and cancer resistance mechanisms. At the UTS School of Pharmacy she specialises in the role and regulation of the xenobiotic cascade in drug disposition and in cancer multidrug resistance (MDR). UTSPEAKS: is a free public lecture series presented by UTS experts discussing a range of important issues confronting contemporary Australia. Use the hashtag #utspeaks to tweet about the lecture on Twitter.

1. Resistance in cancer therapy M.BEBAWY – A MEDICATED NATION – 13 SEPT 2011

4. Cancer – Proliferation, Invasion & Metastasis Schmidt CC. Magazine 2 (1), 2007

5. Resistance Gong J, Jaiswal R, et al . Cancer Treatment Reviews 2011 (in press) Increased drug efflux Altered molecular targets Vesicular sequestration Increased drug metabolism Decreased drug influx Increased DNA repair Altered cellular death apparatus Altered cell cycle checkpoints

6. Multiple Drug Resistance (MDR) Unique Resistance – cross resistance Cause of treatment failure in 90% patients with metastatic disease Functionally redundant Poor prognosis and outcome

7. DRUG EFFLUX Fu, et al. Int. J. Cancer 109, 174-181, 2004

8. MDR ACQUISITION

9. DRUG INDUCED MDR Kota BP, et al . Pharmacological Research 62 (2010) 426–431

10. CELL COMMUNICATION

12. Microparticles: Bind to Cancer Cells CEM + VLBMP

13. MICROPARTICLES: Alternative Cancer MDR Pathway Bebawy M et al ., Leukemia (2009) 23, 1643–1649

17. MPs shed MPs transfer nucleic acids to sensitive cells to reduce drug uptake

18. IMPLICATIONS